HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer.

AbstractPURPOSE:
To determine if head and neck (H/N) cancer patients receiving daily amifostine during radiation therapy (RT) experienced clinical benefit (improvement in their ability to carry out normal functions with reduced discomfort) compared to nonamifostine treated patients.
METHODS AND MATERIALS:
This was an open-label, multi-institutional randomized trial in 303 H/N cancer patients treated with RT +amifostine. Clinical benefit was measured using an 8-item validated Patient Benefit Questionnaire (PBQ) during and up to 11 months after RT.
RESULTS:
301 patients completed one or more PBQ assessments. Amifostine patients had significantly better PBQ scores (p < 0.05) than controls. The improvement in PBQ scores was most significant during chronic xerostomia.
CONCLUSIONS:
Amifostine use results in improved Patient Benefit Questionnaire (PBQ) scores, which is indicative of improved oral toxicity related outcomes and improved clinical benefit. Less oral toxicity should lead to preservation of late dental and oral health, and improvements in activities such as diet, nutrition, and sleep.
AuthorsT Wasserman, J I Mackowiak, D M Brizel, W Oster, J Zhang, P J Peeples, R Sauer
JournalInternational journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 48 Issue 4 Pg. 1035-9 (Nov 01 2000) ISSN: 0360-3016 [Print] United States
PMID11072160 (Publication Type: Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Radiation-Protective Agents
  • Amifostine
Topics
  • Activities of Daily Living
  • Adult
  • Aged
  • Amifostine (therapeutic use)
  • Combined Modality Therapy
  • Data Interpretation, Statistical
  • Follow-Up Studies
  • Head and Neck Neoplasms (radiotherapy)
  • Humans
  • Longitudinal Studies
  • Middle Aged
  • Radiation-Protective Agents (therapeutic use)
  • Saliva (metabolism)
  • Surveys and Questionnaires
  • Treatment Outcome
  • Xerostomia (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: